BioStock: Sprint Bioscience focuses on developing internal programs and partnering
When research company Sprint Bioscience publishes its report for the third quarter, the focus is on development of the internal pharmaceutical programs and new partnerships. The company had a busy schedule at BioEurope, which took place this week in Leipzig, Germany, and it continued to see great interest in the VADA and DISA programs. BioStock talked to CEO Erik Kinnman about partnerships, the upcoming rights issue and what lies ahead.
Read the full article about the Sprint Biosciences latest quarter at biostock.se/en:
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se/en